Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria

Sep.01
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
According to Law360 on August 31, 2026, a federal judge in North Carolina ruled that a patent sublicense between R.J. Reynolds Vapor Co. and Juul Labs Inc. relieves Reynolds of its obligation to continue paying royalties to Altria Client Services LLC over Vuse Alto. A jury had previously found that Vuse Alto infringed three Altria patents and awarded approximately $95.2 million in past damages, after which Reynolds was ordered to pay an ongoing royalty equal to 5.25% of positive net sales. The new ruling finds that a valid sublicense can eliminate future infringement, potentially ending what Altria described as hundreds of millions of dollars in future royalties.

Key Points

  • A U.S. federal court ruled that an effective Juul sublicense can eliminate future infringement and end Reynolds’ ongoing Vuse Alto royalty obligation to Altria.
  • A 2022 jury awarded Altria approximately $95.2 million after finding that Vuse Alto infringed three patents.
  • Reynolds had been required to pay an ongoing royalty equal to 5.25% of positive net sales of covered Vuse Alto products.
  • Altria said the new ruling relieves Reynolds of obligations involving potentially “hundreds of millions of dollars” in royalties.

2Firsts

September 1, 2026

According to Law360 on August 31, 2026, the U.S. District Court for the Middle District of North Carolina ruled that a patent sublicense between R.J. Reynolds Vapor Co. and Juul Labs Inc. relieves Reynolds of its obligation to continue paying royalties to Altria Client Services LLC over its Vuse Alto products. The August 14 ruling had initially been sealed and became public after the parties submitted a proposed redacted version.

The decision is the latest development in a long-running vape patent dispute. In September 2022, a federal jury found that Reynolds’ Vuse Alto infringed three Altria pod-related patents and awarded Altria approximately $95.2 million in past damages.

The court subsequently imposed an ongoing royalty equal to 5.25% of Vuse Alto’s positive net sales.

2022 Patent Verdict Created a 5.25% Ongoing Royalty

The 2022 jury awarded Altria $95,233,292 for infringement through June 30, 2022.

The parties subsequently agreed that Reynolds would pay a 5.25% running royalty on positive net sales of Vuse Alto pods and power units from July 1, 2022 through entry of judgment.

In January 2023, the court ordered Reynolds to continue paying a 5.25% royalty on positive net sales of covered Vuse Alto products until expiration of the last relevant patent.

That arrangement meant Reynolds’ royalty payments would continue to rise with covered Vuse Alto sales.

Juul Sublicense Becomes Key to Ending Future Royalties

R.J. Reynolds later entered into an intellectual property sublicense with Juul.

Reynolds argued that the agreement authorized its use of the relevant patent rights and therefore eliminated future infringement and the associated ongoing royalty obligation.

U.S. District Judge William L. Osteen Jr. agreed in his August 14 opinion.

The court reasoned that a valid license or sublicense can prevent future infringement. If a licensee or sublicensee complies with the agreement while practicing the patent, the underlying use is effectively authorized by the patent holder.

As a result, once Reynolds obtained a valid sublicense through Juul, its continued use of the relevant patent rights no longer supported an ongoing infringement royalty.

Court Rejects Altria’s Argument That Entire Sublicense Was Invalid

Altria argued that because the court had previously found part of the Reynolds-Juul sublicense invalid, the entire agreement should be treated as void.

The court rejected that position.

Judge Osteen pointed to a severability clause in the agreement, concluding that Juul and Reynolds intended invalid or unenforceable provisions to be removed without invalidating the remainder of the contract.

The court therefore found that problems with one portion of the sublicense did not eliminate the agreement as a whole.

Altria Says Hundreds of Millions in Royalties Are at Stake

The financial implications could be significant.

In an August 28 joint filing over how much of the ruling should be made public, Altria argued for full disclosure and said the public had a right to understand why the court had relieved Reynolds of an obligation involving “hundreds of millions of dollars” in royalties.

Reynolds argued that redactions were appropriate because earlier filings involving the licensing arrangements had also been sealed.

Counsel for the parties did not immediately respond to Law360 requests for comment.

Altria, Juul and Reynolds Are Linked Through a Complex IP History

Altria previously held an approximately 35% minority economic interest in Juul.

In March 2023, Altria exchanged its entire Juul stake for a non-exclusive, irrevocable global license to certain Juul heated tobacco intellectual property, ending its equity investment in the company.

The present dispute, however, involves a separate layer of intellectual property rights.

According to Law360, Juul maintains that an earlier agreement with Altria gave it rights to sublicense certain Altria patents. Reynolds relied on a later sublicense from Juul to argue that its future Vuse Alto sales were authorized rather than infringing.

The case illustrates how legacy investment agreements, patent licenses and sublicenses can continue to affect commercial liabilities even after corporate ownership relationships have ended.

Ruling Ends Future Royalty Issue, Not Earlier Infringement Verdict

The new ruling does not overturn the 2022 jury finding that Vuse Alto infringed Altria patents, nor does it erase the approximately $95.2 million award for past infringement.

Instead, the court addressed a narrower commercial and legal issue:

whether a later valid sublicense from Juul could eliminate future infringement and the continuing royalty obligation attached to it.

The court concluded that it could.

For Reynolds, the decision potentially removes a 5.25% royalty burden from future covered Vuse Alto sales. For Altria, it could end a royalty stream that had previously been expected to continue through the life of the relevant patents.

Follow 2Firsts for timely updates on global tobacco and nicotine patent litigation, intellectual property transactions and corporate developments.

Cover Image generated by AI

China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang Industrial Co., Ltd. has filed a patent application for an oral nicotine delivery product designed to let users actively adjust nicotine release. The product embeds two types of nicotine reservoirs with different wall thicknesses and positions inside a deformable matrix. Pressure applied with the tongue or lips can rupture the reservoirs and accelerate nicotine release. In simulated oral tests, several patent examples showed sharply higher peak nicotine release rates as applied force increased from 0 N to 1 N and 3 N. The filing explores a shift from preset release profiles toward user-triggered nicotine delivery.
Sep.01
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
A study by CDC Foundation researchers found no sustained decline in e-cigarette sales across Alabama, Oklahoma and Louisiana, the first three U.S. states to implement e-cigarette directory laws. Louisiana initially saw a significant sales decline, followed by a rebound and a persistent reduction in product availability. Sales also shifted from nontobacco-flavored disposables toward prefilled cartridges, with Vuse Alto driving much of the increase in menthol cartridges. By April 2025, unlisted products still accounted for more than half of e-cigarette nicotine sales in all three states.
Sep.18